SOBR Safe (SOBR) 10-K 13 Apr 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 25, 2016
Document And Entity Information
Entity Registrant Name	TransBiotec, Inc.
Entity Central Index Key	1,425,627
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		67,751,068
Entity Public Float		$ 876,428
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,015

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets
Cash	$ 7,851	$ 623
Total current assets	$ 7,851	623
Fixed assets - net		454
Total Assets	$ 7,851	1,077
Current liabilities
Accounts payable	622,129	484,260
Accrued interest payable	182,678	407,684
Notes payable - current - related parties	489,095	697,225
Notes payable - current, net	$ 157,324	871,694
Notes payable - derivitive liability payable		25,456
Stock subscription payable	$ 55,882	28,067
Related party payables	412,656	296,265
Other payables	242,612	241,922
Total current liabilities	$ 2,162,376	3,052,573
Long-Term Liabilities
Notes payable - related parties		43,298
Total Liabilities	$ 2,162,376	$ 3,095,871
Stockholders' Deficit
Preferred stock, $.00001 par value; 25,000,000 shares authorized; No shares issued and outstanding as of December 31, 2015 and December 31, 2014, respectively
Series A Convertible Preferred stock, $.00001 par value; 3,000,000 shares authorized; No shares issued and outstandingas of December 31, 2015 and December 31, 2014, respectively
Common stock, $.00001 par value; 100,000,000 shares authorized; 60,251,068 and 58,416,660 shares issued and outstanding as of December 31, 2015 and December 31, 2014, respectively	$ 602	$ 585
Additional paid in capital	14,353,628	12,716,630
Accumulated deficit	(16,468,956)	(15,777,222)
Total Transbiotec, Inc. stockholders' deficit	(2,114,726)	(3,060,007)
Noncontrolling interest	(39,799)	(34,787)
Total Stockholders' Deficit	(2,154,525)	(3,094,794)
Total Liabilities and Stockholders' Deficit	$ 7,851	$ 1,077

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Stockholders' Equity
Preferred stock par value	$ .00001	$ .00001
Preferred stock shares authorized	25,000,000	25,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Series A Convertible Preferred stock par value	$ .00001	$ .00001
Series A Convertible Preferred stock shares authorized	3,000,000	3,000,000
Series A Convertible Preferred stock shares issued	0	0
Series A Convertible Preferred stock shares outstanding	0	0
Common stock par value	$ .00001	$ .00001
Common stock shares authorized	100,000,000	100,000,000
Common stock shares issued	60,251,068	58,416,660
Common stock shares outstanding	60,251,068	58,416,660

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Consolidated Statements Of Operations
Revenues
Operating expenses:
Amortization & depreciation	$ 454	$ 776
General and administrative	446,983	505,552
Total operating expenses	447,437	506,328
Loss from operations	(447,437)	(506,328)
Other income (expense):
Gain/(Loss) on fair value adjustment - derivatives	25,456	$ (21,559)
Gain on debt reversal	485
Interest expense	(251,500)	$ (188,046)
Interest expense - beneficial conversion feature	(23,750)	(32,996)
Total other income (expense)	(249,309)	(242,601)
Loss before provision for income taxes	$ (696,746)	$ (748,929)
Provision for income tax
Net loss	$ (696,746)	$ (748,929)
Less: Net loss attributable to noncontrolling interest	5,012	4,367
Net loss attributable to TranBioTec, Inc.	$ (691,734)	$ (744,562)
Net loss per share
(Basic and fully diluted)	$ (0.01)	$ (0.02)
Weighted average number of common shares outstanding	59,261,114	39,215,919

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)	Common Stock [Member]	Additional Paid-In Capital	Accumulated Deficit	Stockholders' Equity - TransBiotec Inc.	Noncontrolling Interest	Total
Beginning Balance, Shares at Dec. 31, 2013	34,146,712
Biginning Balance, Amount at Dec. 31, 2013	$ 342	$ 12,415,639	$ (15,032,660)	$ (2,616,679)	$ (30,420)	$ (2,647,099)
Stock issued for services, Shares	154,520
Stock issued for services, Amount	$ 2	3,057		3,059		3,059
Stock conversion of note payable , Shares	24,115,428
Stock conversion of note payable, Amount	$ 241	66,878		67,119		67,119
Paid in capital - beneficial conversion feature		15,000		15,000		15,000
Paid in capital - stock option expense		69,886		69,886		69,886
Paid in capital - Equity obligation settlement at fair value		146,170		146,170		146,170
Share exchange - noncontrolling interest					$ (4,367)	(4,367)
Net Loss			$ (744,562)	(744,562)		(744,562)
Ending Balance, Shares at Dec. 31, 2014	58,416,660
Ending Balance, Amount at Dec. 31, 2014	$ 585	12,716,630	$ (15,777,222)	(3,060,007)	$ (34,787)	(3,094,794)
Stock issued for cash, Shares	834,408
Stock issued for cash, Amount	$ 7	1,495		1,502		1,502
Stock conversion of note payable , Shares	1,000,000
Stock conversion of note payable, Amount	$ 10	3,890		3,900		3,900
Paid in capital - beneficial conversion feature		25,000		25,000		25,000
Paid in capital - stock option expense		26,229		26,229		26,229
Paid in capital - Gain on related party debt conversion		1,472,384		1,472,384		1,472,384
Paid in capital - Gain on related party share issuances		12,500		12,500		12,500
Share exchange - noncontrolling interest					$ (5,012)	(5,012)
Paid in capital - Gain on related party forgiveness of debt		108,000		108,000		108,000
Net Loss			$ (691,734)	(691,734)		(691,734)
Ending Balance, Shares at Dec. 31, 2015	60,251,068
Ending Balance, Amount at Dec. 31, 2015	$ 602	$ 14,353,628	$ (16,468,956)	$ (2,114,726)	$ (39,799)	$ (2,154,525)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Operating Activities:
Net loss	$ (691,734)	$ (744,562)
Adjustments to reconcile net loss to net cash provided by (used for) operating activities:
Amortization & depreciation	454	776
Change in fair value of derivative liabilities	(25,456)	21,559
Note payable beneficial conversion expense	23,750	$ 32,996
Stock Options Expense	$ 26,229
Stock based compensation		$ 69,888
Changes in assets and liabilities:
Accounts payable	$ 221,768	64,730
Stock subscription payable	27,815
Accrued interest payable	(136,726)	138,734
Related party payable	116,391	105,500
Notes payable	321,172
Other payable	(4,322)	(530)
Net cash used for operating activities	$ (120,749)	$ (310,909)
Investing Activities:
Net cash used for investing activities
Financing Activities:
Proceeds from share issuances	$ 1,502
Net proceeds from notes payable	154,315	$ 347,266
Net payments from notes payable	(27,840)	(35,734)
Net cash provided by financing activities	127,977	311,532
Net Change In Cash	7,228	$ 623
Cash At The Beginning Of The Period	623
Cash At The End Of The Period	7,851	$ 623
Schedule Of Non-Cash Investing And Financing Activities
Debt converted to capital	1,472,384	$ 96,470
Issuances of shares to settle accrued interest	3,900
Gain on forgiveness of debt - related party	108,000
Supplemental Disclosure
Cash paid for interest	$ 13,825	$ 9,000
Cash paid for income taxes

NOTE 1. ORGANIZATION, OPERATION

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	TransBiotec, Inc. ("TransBiotec – DE"), formerly Imagine Media LTD., was incorporated August, 2007 in the State of Delaware. A corporation also named TransBiotec, Inc. ("TransBiotec – CA") was formed in the state of California July 4, 2004. Effective September 19, 2011 TransBiotec - DE was acquired by TransBiotec - CA in a transaction classified as a reverse acquisition as the shareholders of TransBiotec - CA retained the majority of the outstanding common stock of TransBiotec - DE after the share exchange. The financial statements represent the activity of TransBiotec - CA from July 4, 2004 forward, and the consolidated activity of TransBiotec - DE and TransBiotec - CA from September 19, 2011 forward. TransBiotec - DE and TransBiotec - CA are hereinafter referred to collectively as the "Company". The Company has developed and plans to market and sell a non-invasive alcohol sensing system which includes an ignition interlock. The Company has not generated any revenues from its operations. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles ("GAAP") as promulgated in the United States of America. Principles of consolidation The accompanying consolidated financial statements include the amounts of the Company and its majority owned subsidiary, Transbiotec-CA. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Specifically, such estimates were made by the Company for the valuation of derivative liability, stock compensation and beneficial conversion feature expenses. Actual results could differ from those estimates. Cash The Company considers all highly liquid investments with an original maturity of three months or less as cash equivalents. The Company does not have any cash equivalents as of December 31, 2015 and December 31, 2014. Property and equipment Property and equipment are recorded at cost and depreciated under straight line methods over each item's estimated useful life. Income tax The Company accounts for income taxes pursuant to ASC 740. Under ASC 740 deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Net loss per share The net loss per share is computed by dividing the net loss by the weighted average number of shares of common outstanding. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of the Company, subject to anti-dilution limitations. The Company has 30,038,041 stock options that can be converted to common stock if exercised. Financial Instruments SC Topic 820 defines fair value, establishes a framework for measuring fair value, establishes a three-level valuation hierarchy for disclosure of fair value measurement and enhances disclosure requirements for fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows: Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 – Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. Level 3 – Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The carrying value of cash, accounts payable, accrued expenses, notes payable, related party payables, and other payable approximates their fair values due to their short-term maturities. Long-Lived Assets In accordance with ASC 350, the Company regularly reviews the carrying value of intangible and other long-lived assets for the existence of facts or circumstances, both internally and externally, that may suggest impairment. If impairment testing indicates a lack of recoverability, an impairment loss is recognized by the Company if the carrying amount of a long-lived asset exceeds its fair value. Beneficial Conversion Features From time to time, the Company may issue convertible notes that may contain an embedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method. Derivative Instruments The fair value of derivative instruments is recorded and shown separately under current liabilities. Changes in fair value are recorded in the consolidated statement of income under other income (expenses). The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instruments is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a weighted average Black-Sholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. Stock based compensation The Company has share-based compensation plans under which employees, consultants, suppliers and directors may be granted restricted stock, as well as options and warrants to purchase shares of Company common stock at the fair market value at the time of the grant. Stock-based compensation cost to employees is measured by the Company at the grant date, based on the fair value of the award, over the requisite service period under ASC718. For options issued to employees, the Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit. Grants of stock to non-employees and other parties are accounted for in accordance with the ASC 505. Recent accounting pronouncement In June 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders' equity. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. The Company adopted ASU 2014-10 during the quarter ended June 30, 2014, thereby no longer presenting or disclosing any information required by Topic 915. In August 2014, the FASB issued the FASB Accounting Standards Update No. 2014-15 "Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern ("ASU 2014-15"). In connection with preparing financial statements for each annual and interim reporting period, an entity's management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). Management's evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued (or at the date that the financial statements are available to be issued when applicable). Substantial doubt about an entity's ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). The term probable is used consistently with its use in Topic 450, Contingencies. When management identifies conditions or events that raise substantial doubt about an entity's ability to continue as a going concern, management should consider whether its plans that are intended to mitigate those relevant conditions or events will alleviate the substantial doubt. The mitigating effect of management's plans should be considered only to the extent that (1) it is probable that the plans will be effectively implemented and, if so, (2) it is probable that the plans will mitigate the conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. If conditions or events raise substantial doubt about an entity's ability to continue as a going concern, but the substantial doubt is alleviated as a result of consideration of management's plans, the entity should disclose information that enables users of the financial statements to understand all of the following (or refer to similar information disclosed elsewhere in the footnotes): a. Principal conditions or events that raised substantial doubt about the entity's ability to continue as a going concern (before consideration of management's plans). b. Management's evaluation of the significance of those conditions or events in relation to the entity's ability to meet its obligations. c. Management's plans that alleviated substantial doubt about the entity's ability to continue as a going concern. If conditions or events raise substantial doubt about an entity's ability to continue as a going concern, but the substantial doubt is not alleviated after consideration of management's plans, an entity should include a statement in the footnotes indicating that there is substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or available to be issued). Additionally, the entity should disclose information that enables users of the financial statements to understand all of the following: a. Principal conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. b. Management's evaluation of the significance of those conditions or events in relation to the entity's ability to meet its obligations. c. Management's plans that are intended to mitigate the conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for the annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact of the adoptions of ASU 2014-15 on its consolidated financial statements. Minority interest (Noncontrolling interest) A subsidiary of the Company has minority members, representing ownership interests of 1.38% at December 31, 2015 and December 31, 2014. The Company accounts for these minority, or noncontrolling interests pursuant to ASC 810-10-65 whereby gains and losses in a subsidiary with a noncontrolling interest are allocated to the noncontrolling interest based on the ownership percentage of the noncontrolling interest, even if that allocation results in a deficit noncontrolling interest balance.

NOTE 2. RELATED PARTY TRANSACTI

NOTE 2. RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
NOTE 2. RELATED PARTY TRANSACTIONS	As of December 31, 2015 and December 31, 2014, the Company had payables due to officers, for accrued compensation and services of $412,656 and $296,265 respectively. The Company amended a note payable agreement with Lanphere Law Group, the company's largest shareholder, which forgave $108,000 of the principal balance. The original principal balance on the note was $214,334.50 and the new principal balance on the note after the debt forgiveness is $106,334.50. The Company entered into a lease agreement with Lanphere Law Group, whereas the Company is the tenant and is paying monthly rent of $4,100.

NOTE 3. PROPERTY & EQUIPMENT

NOTE 3. PROPERTY & EQUIPMENT	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
NOTE 3. PROPERTY & EQUIPMENT	Property and equipment values recorded at cost are as follows: Dec. 31, 2015 Dec. 31, 2014 Office and Lab Equipment $ 32,127 $ 32,127 Furniture and fixtures 11,556 11,556 43,683 43,683 Less accumulated depreciation (43,683 ) (43,229 ) Property & Equipment, Net $ - $ 454 Depreciation expense for the years ended December 31, 2015 and 2014 was $454 and $776, respectively.

NOTE 4. NOTES PAYABLE

NOTE 4. NOTES PAYABLE	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
NOTE 4. NOTES PAYABLE	December 31, 2015 December 31, 2014 Note payable to related party, unsecured, due 8/3/2012, interest rate 0%. Currently in default. $ 1,950 $ 1,950 Notes payable to related party, unsecured, due 12/31/2012, interest rate 0%. Currently in default. $ 11,810 $ 11,810 Note payable to related party, unsecured, $731,763, 5-years at 0% simple interest, due 7/1/2016, payment amounts vary each month, various late penalties. $ 180,001 $ 726,763 Note payable to non-related party, unsecured, due 2/8/12, quarterly interest due, convertible at holder's option at $0.3235688 per TBT - DE share, interest rate 30%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 10,000 $ 10,000 Note payable to non-related party, unsecured, due 2/8/12, quarterly interest due, convertible at holder's option at $0.3235688 per TBT - DE share, interest rate 30%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 25,000 $ 25,000 Note payable to non-related party, unsecured, due 2/17/12, quarterly interest due, convertible at holder's option at $0.3235688 per TBT - DE share, interest rate 30%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 25,000 $ 25,000 Note payable to non-related party, unsecured, due 2/18/12, quarterly interest due, convertible at holder's option at $0.3235688 per TBT - DE share, interest rate 30%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 10,000 $ 10,000 Note payable to non-related party, unsecured, due 2/18/13, annual interest due, convertible at holder's option at $0.3235688 per TBT-DE share, interest rate 18%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 750 $ 750 Note payable to non-related party, unsecured, due 2/18/13, annual interest due, convertible at holder's option at $0.3235688 per TBT-DE share, interest rate 18%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 6,875 $ 6,875 Note payable to non-related party, unsecured, due 2/15/13, annual interest due, convertible at holder's option at $0.3235688 per TBT-DE share, interest rate 12%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 2,500 $ 2,500 Note payable to non-related party, unsecured, due 2/20/13, annual interest due, convertible at holder's option at $0.3235688 per TBT-DE share, interest rate 12%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 3,750 $ 3,750 Note payable to non-related party, unsecured, due 2/21/13, annual interest due, convertible at holder's option at $0.3235688 per TBT-DE. share, interest rate 12%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 2,625 $ 2,625 Note payable to non-related party, unsecured, due 3/20/13, annual interest due, convertible at holder's option at $0.3235688 per TBT-DE share, interest rate 12%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 5,433 $ 5,433 Note payable to non-related party, unsecured, due 3/22/13, annual interest due, convertible at holder's option at $0.3235688 per TBT-DE share, interest rate 12%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 3,203 $ 3,203 Note payable to non-related party, unsecured, due 4/19/13, annual interest due, convertible at holder's option at 51% of market as defined, interest rate 8%, conversion limited to total beneficial ownership of 4.99%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue and/or the continued conversion of the company's stock. $ - $ 6,605 Note payable to non-related party, unsecured, due 08/29/2013, simple interest 8% convertible at holder's option at $.249 per TBT-CA share. $ 15,000 $ 15,000 Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Note payable to related party, unsecured, due 03/01/2013, simple interest 9%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 5,000 $ 5,000 Note payable to non-related party, unsecured, due 12/13/2013, simple interest 7%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 5,342 Note payable to non-related party, unsecured, due 01/31/2013, simple interest 18%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 3,938 $ 3,938 Note payable to non-related party, unsecured, due 01/07/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 15,000 Note payable to non-related party, unsecured, due 01/15/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 5,000 Note payable to non-related party, unsecured, due 01/20/2014, simple interest 7%, default interest 10%, $ - $ 65,272 Stock option issued as an additional transaction cost for receipt of funds from note payable. Note payable to related party, unsecured, due 01/23/2014, simple interest 9%. Currently in default. $ 50,000 $ 50,000 Note payable to non-related party, unsecured, due 03/28/2013, $13,000 in interest (1 month). $ - $ 17,000 Note payable to non-related party, unsecured, due 04/28/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 9,440 Note payable to non-related party, unsecured, due 05/05/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 50,060 Note payable to related party, unsecured, due 07/02/2014, simple interest 9%. $ 15,000 $ 15,000 Note payable to non-related party, unsecured, due 09/19/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 10,000 Note payable to non-related party, unsecured, due 07/29/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 1,900 Note payable to non-related party, unsecured, due 07/25/2013, simple interest 18%. Currently in default. $ 2,000 $ 2,000 Note payable to non-related party, unsecured, due 09/19/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 65,000 Note payable to non-related party, unsecured, due 12/27/2013, simple interest 9% quarterly, Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 15,000 $ 15,000 Note payable to non-related party, unsecured, due 09/29/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 20,000 Note payable to non-related party, unsecured, due 10/28/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 2,500 Note payable to non-related party, unsecured, due 10/29/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 10,000 Note payable to non-related party, unsecured, due 11/10/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 5,000 Note payable to related party, unsecured, due 11/12/2014, simple interest 9%, Convertible at $0.04 per share, currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 11,000 $ 11,000 Note payable to non-related party, unsecured, due 11/20/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 20,000 Note payable to non-related party, unsecured, due 12/02/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 5,000 Note payable to non-related party, unsecured, due 1/27/2014, simple interest 10%, $ - $ 4,235 Note payable to non-related party, unsecured, due 1/07/2015, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 25,000 Note payable to non-related party, unsecured, due 1/28/2015, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 1,253 Note payable to non-related party, unsecured, due 1/29/2015, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 3,500 Note payable to non-related party, unsecured, due 2/10/2015, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 990 Note payable to non-related party, unsecured, due 2/17/2015, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 4,500 Note payable to non-related party, unsecured, due 2/20/2015, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 5,000 Note payable to non-related party, unsecured, due 3/10/2015, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 2,500 Note payable to non-related party, unsecured, due 3/31/2015, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 2,500 Note payable to non-related party, unsecured, due 4/03/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 5,890 Note payable to related party, unsecured, due 4/08/2015, simple interest 7%, Convertible at $0.0072 per share. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 15,000 $ 15,000 Note payable to non-related party, unsecured, due 4/10/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 4,331 Note payable to non-related party, unsecured, due 4/27/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 2,500 Note payable to non-related party, unsecured, due 5/13/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 5,360 Note payable to non-related party, unsecured, due 5/26/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 895 Note payable to non-related party, unsecured, due 9/11/2014, simple interest 10%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ 5,000 $ 5,000 Note payable to non-related party, unsecured, due 6/10/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 3,207 Note payable to non-related party, unsecured, due 6/17/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 600 Note payable to related party, unsecured, due 8/05/2015, simple interest 7%, default interest 10%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ 10,000 $ 10,000 Note payable to non-related party, unsecured, due 7/09/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 3,750 Note payable to non-related party, unsecured, due 9/03/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 1,000 Note payable to non-related party, unsecured, due 10/19/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 1,486 Note payable to non-related party, unsecured, due 10/22/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 3,500 Note payable to non-related party, unsecured, due 10/28/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 4,360 Note payable to non-related party, unsecured, due 11/11/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 5,810 Note payable to non-related party, unsecured, due 11/19/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 15,000 Note payable to related party unsecured, due 12/02/2015, simple interest 7%, default interest 10%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Currently in default. $ 106,334 $ 214,334 Note payable to non-related party, unsecured, due 3/26/2016, simple interest 8%, convertible at $0.0017 per share. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Currently in default. $ 25,000 $ - Note payable to related party, unsecured, due 4/11/2016, simple interest 10%. $ 13,000 $ - Note payable to related party, unsecured, due 11/11/2015, simple interest 10%. Currently in default. $ 45,000 $ - Note payable to non-related party, unsecured, due 11/11/2015, simple interest 10%. Currently in default. $ 2,500 $ - Note payable to related party, unsecured, due 12/26/2015, simple interest 10%. Currently in default. $ 25,000 $ - $ 652,669 $ 1,617,217 Less note discounts (6,250 ) (5,000 ) Less current - related parties (489,095 ) (697,225 ) Less current – non-related parties (157,324 ) (871,694 ) Long-term – related parties $ - $ 43.298 Required principal payments from December 31, 2015 forward are as follows: 2016 $ 652,669 2017 $ - 2018 $ - 2019 $ - 2020 $ - $ 652,669 Interest expense under notes payable for the years ended December 31, 2014 and December 31, 2015 was $188,046 and $198,327, respectively. During the years ended December 31, 2014 and December 31, 2015 the Company recognized a beneficial conversion feature expense on borrowing from convertible notes of $32,996 and $23,750, respectively. During the years ended December 31, 2014 and December 31, 2015 the unamortized note discount from the beneficial conversion feature was $5,000 and $6,250, respectively. In 2012 the company borrowed $110,000 under convertible notes with a variable conversion price based on a percentage of market price. Notes converted at December 31, 2014 and December 31, 2015 were $103,395 and $103,395, respectively. The Company determined that these notes have an embedded derivative and are therefore accounted for at fair value. The Company recorded fair market value adjustments for the years ended ended December 31, 2014 and December 31, 2015 of $21,559 and $(25,456), respectively. The fair market value adjustments were based on the Black-Sholes method using the following assumptions: risk free rates ranging between 0.10% - 0.21%, dividend yield of 0%, expected life of 1 year, volatility between 128% - 354%. The fair value derivative liability under the notes as of December 31, 2014 and December 31, 2015 was $25,456 and none, respectively.

NOTE 5. INCOME TAXES

NOTE 5. INCOME TAXES	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
NOTE 5. INCOME TAXES	Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses. These loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur. At December 31, 2014 and 2015 the Company had net operating loss carry forwards of approximately $6,383,000 and $7,048,000 respectively, that may be offset against future taxable income, if any, ratably through 2035. These carry-forwards are subject to review by the Internal Revenue Service. The deferred tax asset of at each date of $1,277,000 and $1,410,000 created by the net operating losses has been offset by a 100% valuation allowance because the likelihood of realization of the tax benefit cannot be determined. The change in the valuation allowance in 2014 and 2015 was $123,000 and $133,000. The effects of temporary differences that gives rise to significant portions of deferred tax assets at December 31, 2015 and 2014 are as follows: Dec. 31, 2015 Dec. 31, 2014 Deferred tax asset Federal $ 1,057,000 $ 958,000 State 353,000 319,000 Valuation allowance (1,410,000 ) (1,277,000 ) Net deferred tax asset $ - $ - There is no current or deferred tax expense for the years ended December 31, 2015 and 2014. The Company has not filed tax returns however management believes there are no taxes due as of December 31, 2014 and 2015. There was no Federal income tax expense for the years ended December 31, 2015 and 2014 due to the Company's net losses. For the years ended December 31, 2015 and 2014 state income tax expense was zero. The company includes interest and penalties arising from the underpayment of income taxes in the consolidated statements of operations in general and administrative expenses. The tax years that remain subject to examination by major taxing jurisdictions are those for the tax year of 2015, 2014, and 2013.

NOTE 6. STOCK OPTIONS AND SUBSC

NOTE 6. STOCK OPTIONS AND SUBSCRIPTIONS PAYABLE	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
NOTE 6. STOCK OPTIONS AND SUBSCRIPTIONS PAYABLE	The Company accounts for employee and non-employee stock options under ASC 718 and ASC 505, whereby option costs are recorded based on the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Unless otherwise provided for, the Company covers option exercises by issuing new shares. The Company's stock option activity is described below. Non-employee stock options At the beginning of 2012, the Company had 22,500 options outstanding for shares in Transbiotec – CA. The fair value of the option grants was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rate of 2.67%, dividend yield of 0%, expected life of five years, volatility of 100%. During the year ended December 31, 2012 no options were exercised or expired, leaving a December 31, 2012 outstanding balance of 22,500 non-employee stock options, exercisable at prices from $0.10 - $0.15 per share with the option terms expiring from January 2012 through January 2015. All of these options are for the stock of TransBiotec - CA. During the year ended December 31, 2014, 20,000 options were exercised, leaving a December 31, 2014 outstanding balance of 2,500 non-employee stock options, exercisable at $0.10 per share with the option terms expiring in January 2015. During the year ended December 31, 2015, no options were exercised as all outstanding options expired in January 2015 leaving no outstanding balance of non-employee stock options in the stock of Transbiotec-CA at December 31, 2015. During 2012 the Company granted 29,678 stock options for shares in Transbiotec - DE. The fair value of the option grants was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rate of 0.8%, dividend yield of 0%, expected life of five years, volatility of 189%. No options were exercised or expired, leaving a December 31, 2012 outstanding balance of 29,678 options for Transbiotec – DE. The Company incurred and recorded compensation expense under these stock option grants of $4,042 in 2012. Vested immediately. During 2013 the Company granted 5,321,735 stock options for shares in Transbiotec - DE. The fair value of the option grants was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rates between 7% - 14%, dividend yield of 0%, expected life of five years, volatility between 179% - 186%. No options were exercised or expired, leaving a December 31, 2013 outstanding balance of 5,351,413 options for Transbiotec – DE. The Company incurred and recorded compensation expense under these stock option grants of $145,997 in 2013. Vested immediately. During 2014 the Company granted 8,403,633 stock options for shares in Transbiotec - DE. The fair value of the option grants was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rates between 1.55% - 1.77%, dividend yield of 0%, expected life of five years, volatility between 147% - 178%. No options were exercised or expired, leaving a December 31, 2014 outstanding balance of 13,755,046 options for Transbiotec – DE. The Company incurred and recorded compensation expense under these stock option grants of $69,886 in 2014. Vested immediately. During the year ended December 31, 2015, the Company granted 16,282,995 stock options for shares in Transbiotec - DE. The fair value of the option grants was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rate between 1.37% - 1.68%, dividend yield of 0%, expected life of five years, a volatility range of 172% - 174%. No options were exercised or expired, leaving a December 31, 2015 outstanding balance of 30,038,041 options for Transbiotec – DE. The Company incurred and recorded compensation expense under these stock option grants of $27,731 during the year ended December 31, 2015. Vested immediately. A summary of stock option activity for California is as follows: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2014 2,500 $ .10 Granted - - Exercised - - Forfeited 2,500 .10 Outstanding at December 31, 2015 - $ - A summary of stock option activity for Delaware is as follows: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2014 13,755,046 $ .0295 Granted 16,282,995 .0015 Exercised - - Forfeited - - Outstanding at December 31, 2015 30,038,041 $ .0143 Following is a summary of the status of options for Delaware outstanding at December 31, 2015: Exercise Price Number of Shares Remaining Contractual Life Weighted Average Exercise Price Exercised at December 31, $ 0.0900 29,678 2 years 0.0900 - $ 0.1700 83,333 3 years 0.1700 - $ 0.1700 27,778 3 years 0.1700 - $ 0.1700 362,624 3 years 0.1700 - $ 0.1300 80,914 3 years 0.1300 - $ 0.1300 429,086 3 years 0.1300 - $ 0.0600 38,000 3 years 0.0600 - $ 0.0400 250,000 3 years 0.0400 - $ 0.0400 1,625,000 3 years 0.0400 - $ 0.0500 400,000 3 years 0.0500 - $ 0.0400 75,000 3 years 0.0400 - $ 0.0400 300,000 3 years 0.0400 - $ 0.0200 300,000 3 years 0.0200 - $ 0.0200 1,200,000 3 years 0.0200 - $ 0.0400 150,000 3 years 0.0400 - $ 0.0125 1,200,000 4 years 0.0125 $ 0.0150 50,137 4 years 0.0150 - $ 0.0150 140,000 4 years 0.0150 - $ 0.0190 31,256 4 years 0.0190 - $ 0.0161 167,702 4 years 0.0161 - $ 0.0147 204,082 4 years 0.0147 - $ 0.0200 75,000 4 years 0.0200 - $ 0.0198 75,758 4 years 0.0198 - $ 0.0213 165,915 4 years 0.0213 - $ 0.0195 133,262 4 years 0.0195 - $ 0.0188 79,787 4 years 0.0188 - $ 0.0140 229,714 4 years 0.0140 - $ 0.0190 50,000 4 years 0.0190 - $ 0.0127 42,283 4 years 0.0127 - $ 0.0090 213,833 4 years 0.0090 - $ 0.0074 48,649 4 years 0.0074 - $ 0.0060 375,000 4 years 0.0060 - $ 0.0098 612,245 4 years 0.0098 - $ 0.0098 61,224 4 years 0.0098 - $ 0.2500 25,000 4 years 0.2500 - $ 0.0680 450,000 4 years 0.0680 - $ 0.0072 123,828 4 years 0.0072 - $ 0.0056 375,000 4 years 0.0056 - $ 0.0070 250,000 4 years 0.0070 - $ 0.0070 373,714 4 years 0.0070 - $ 0.0041 850,244 4 years 0.0041 - $ 0.0045 2,000,000 4 years 0.0045 - $ 0.0024 150,000 5 years 0.0024 - $ 0.0010 7,625,544 5 years 0.0010 - $ 0.0024 1,770,000 5 years 0.0024 - $ 0.0023 400,782 5 years 0.0023 - $ 0.0012 275,000 5 years 0.0012 - $ 0.0017 1,764,706 5 years 0.0017 - $ 0.0018 2,463,333 5 years 0.0018 - $ 0.0021 285,714 5 years 0.0021 - $ 0.0018 333,333 5 years 0.0018 - $ 0.0018 1,083,333 5 years 0.0018 - $ 0.0018 131,250 5 years 0.0018 - Total 30,038,041 0.0143 Employee stock options The parent company had no outstanding employee stock options. Stock subscriptions received At December 31, 2015, the Company had stock subscriptions received of $55,868 for 6,049,578 common shares to be issued. At December 31, 2015, the Company had stock subscriptions received of $14 for 1,388,575 preferred shares to be issued.

NOTE 7. GOING CONCERN

NOTE 7. GOING CONCERN	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
NOTE 7. GOING CONCERN	The Company has suffered recurring losses from operations and has a working capital deficit and stockholders' deficit, and in all likelihood will be required to make significant future expenditures in connection with continuing marketing efforts along with general administrative expenses. As of December 31, 2015, the accumulated deficit is $16,468,956. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The Company may raise additional capital through the sale of its equity securities, through an offering of debt securities, or through borrowings from financial institutions or others. By doing so, the Company hopes to generate revenues from sales of its alcohol sensing and ignition lock systems. Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern.

NOTE 8. COMMON STOCK

NOTE 8. COMMON STOCK	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
NOTE 8. COMMON STOCK	On February 10, 2014, the Company converted a note payable of $4,650 into 1,291,667 shares of its common stock, with a purchase price $0.0036 per share. On April 24, 2014, the Company exchanged 20,000 of TBT-CA shares for 154,520 TBT-Publico shares at an exchange rate of $7.7263 per share. On May 13, 2014, the Company converted a note payable of $9,000 into 1,764,706 shares of its common stock, with a purchase price $0.0051 per share. On May 30, 2014, the Company converted a note payable of $265, including $210 of accrued interest into 50,000 shares of its common stock, with a purchase price $0.0095 per share. On June 3, 2014, the Company converted a note payable of $5,600, including $1,500 in accrued interest into 1,690,476 shares of its common stock, with a purchase price $0.0042 per share. On July 2, 2014, the Company converted a note payable of $6,360 into 1,766,667 shares of its common stock, with a purchase price $0.0036 per share. On August 19, 2014, the Company converted a note payable of $7,135 into 2,038,571 shares of its common stock, with a purchase price $0.0035 per share. On October 21, 2014, the Company converted a note payable of $6,520 into 2,037,500 shares of its common stock, with a purchase price $0.0032 per share. On October 22, 2014, the Company converted a note payable of $6,270 into 1,959,375 shares of its common stock, with a purchase price $0.0032 per share. On October 29, 2014, the Company converted a note payable of $5,780 into 2,140,741 shares of its common stock, with a purchase price $0.0027 per share. On November 20, 2014, the Company converted a note payable of $4,690 into 2,345,000 shares of its common stock, with a purchase price $0.0020 per share. On November 24, 2014, the Company converted a note payable of $3,985 into 2,344,118 shares of its common stock, with a purchase price $0.0017 per share. On December 16, 2014, the Company converted a note payable of $3,280 into 2,342,857 shares of its common stock, with a purchase price $0.0014 per share. On December 30, 2014, the Company converted a note payable of $1,875 into 2,343,750 shares of its common stock, with a purchase price $0.0008 per share. On June 11, 2015, as an inducement for a loan, the Company issued 834,408 shares of its common stock on said date valued at $1,502 with a purchase price of $0.0018 per share. On August 20, 2015, the Company converted accrued interest of $3,900 into 1,000,000 shares of its common stock, with a purchase price $0.0039 per share.

NOTE 9. COMMITMENTS AND CONTING

NOTE 9. COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
NOTE 9. COMMITMENTS AND CONTINGENCIES	Operating Leases The Company leases its office space under a long-term operating lease expiring in June 2019. Rent expense under this lease was $24,600 and none for the years ended December 31, 2015 and 2014, respectively. As of December 31, 2015, future minimum annual payments under operating lease agreements for years ending December 31 are as follows. 2016 2017 2018 2019 2020 Total Operating leases 49,200 49,200 49,200 24,600 - 172,200 $ 49,200 $ 49,200 $ 49,200 $ 24,600 $ - $ 172,200

NOTE 10. SUBSEQUENT EVENTS

NOTE 10. SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
NOTE 10. SUBSEQUENT EVENTS	As of April 4, 2016, there were 67,751,068 shares of our common stock outstanding held by 148 holders of record and numerous shares held in brokerage accounts. Of these shares, 48,690,401 shares were held by non-affiliates.

NOTE 1. ORGANIZATION, OPERATI17

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2015
Note 1. Organization Operations And Summary Of Significant Accounting Policies Policies
Basis of Presentation	The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles ("GAAP") as promulgated in the United States of America.
Principles of Consolidation	The accompanying consolidated financial statements include the amounts of the Company and its majority owned subsidiary, Transbiotec-CA. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Specifically, such estimates were made by the Company for the valuation of derivative liability, stock compensation and beneficial conversion feature expenses. Actual results could differ from those estimates.
Cash	The Company considers all highly liquid investments with an original maturity of three months or less as cash equivalents. The Company does not have any cash equivalents as of December 31, 2015 and December 31, 2014.
Property and equipment	Property and equipment are recorded at cost and depreciated under straight line methods over each item's estimated useful life.
Income tax	The Company accounts for income taxes pursuant to ASC 740. Under ASC 740 deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
Net loss per share	The net loss per share is computed by dividing the net loss by the weighted average number of shares of common outstanding. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of the Company, subject to anti-dilution limitations. The Company has 30,038,041 stock options that can be converted to common stock if exercised.
Financial Instruments	SC Topic 820 defines fair value, establishes a framework for measuring fair value, establishes a three-level valuation hierarchy for disclosure of fair value measurement and enhances disclosure requirements for fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows: Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 – Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. Level 3 – Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The carrying value of cash, accounts payable, accrued expenses, notes payable, related party payables, and other payable approximates their fair values due to their short-term maturities.
Long-Lived Assets	In accordance with ASC 350, the Company regularly reviews the carrying value of intangible and other long-lived assets for the existence of facts or circumstances, both internally and externally, that may suggest impairment. If impairment testing indicates a lack of recoverability, an impairment loss is recognized by the Company if the carrying amount of a long-lived asset exceeds its fair value.
Beneficial Conversion Features	From time to time, the Company may issue convertible notes that may contain an embedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.
Derivative Instruments	The fair value of derivative instruments is recorded and shown separately under current liabilities. Changes in fair value are recorded in the consolidated statement of income under other income (expenses). The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instruments is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a weighted average Black-Sholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
Stock based compensation	The Company has share-based compensation plans under which employees, consultants, suppliers and directors may be granted restricted stock, as well as options and warrants to purchase shares of Company common stock at the fair market value at the time of the grant. Stock-based compensation cost to employees is measured by the Company at the grant date, based on the fair value of the award, over the requisite service period under ASC718. For options issued to employees, the Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit. Grants of stock to non-employees and other parties are accounted for in accordance with the ASC 505.
Recent accounting pronouncement	In June 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders' equity. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. The Company adopted ASU 2014-10 during the quarter ended June 30, 2014, thereby no longer presenting or disclosing any information required by Topic 915. In August 2014, the FASB issued the FASB Accounting Standards Update No. 2014-15 "Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern ("ASU 2014-15"). In connection with preparing financial statements for each annual and interim reporting period, an entity's management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). Management's evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued (or at the date that the financial statements are available to be issued when applicable). Substantial doubt about an entity's ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). The term probable is used consistently with its use in Topic 450, Contingencies. When management identifies conditions or events that raise substantial doubt about an entity's ability to continue as a going concern, management should consider whether its plans that are intended to mitigate those relevant conditions or events will alleviate the substantial doubt. The mitigating effect of management's plans should be considered only to the extent that (1) it is probable that the plans will be effectively implemented and, if so, (2) it is probable that the plans will mitigate the conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. If conditions or events raise substantial doubt about an entity's ability to continue as a going concern, but the substantial doubt is alleviated as a result of consideration of management's plans, the entity should disclose information that enables users of the financial statements to understand all of the following (or refer to similar information disclosed elsewhere in the footnotes): a. Principal conditions or events that raised substantial doubt about the entity's ability to continue as a going concern (before consideration of management's plans). b. Management's evaluation of the significance of those conditions or events in relation to the entity's ability to meet its obligations. c. Management's plans that alleviated substantial doubt about the entity's ability to continue as a going concern. If conditions or events raise substantial doubt about an entity's ability to continue as a going concern, but the substantial doubt is not alleviated after consideration of management's plans, an entity should include a statement in the footnotes indicating that there is substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or available to be issued). Additionally, the entity should disclose information that enables users of the financial statements to understand all of the following: a. Principal conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. b. Management's evaluation of the significance of those conditions or events in relation to the entity's ability to meet its obligations. c. Management's plans that are intended to mitigate the conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for the annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact of the adoptions of ASU 2014-15 on its consolidated financial statements.
Minority Interest (Noncontrolling Interest)	A subsidiary of the Company has minority members, representing ownership interests of 1.38% at December 31, 2015 and December 31, 2014. The Company accounts for these minority, or noncontrolling interests pursuant to ASC 810-10-65 whereby gains and losses in a subsidiary with a noncontrolling interest are allocated to the noncontrolling interest based on the ownership percentage of the noncontrolling interest, even if that allocation results in a deficit noncontrolling interest balance.

NOTE 3. PROPERTY & EQUIPMENT (T

NOTE 3. PROPERTY & EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2015
Note 3. Property Equipment Tables
Fixed asset values	Property and equipment values recorded at cost are as follows: Dec. 31, 2015 Dec. 31, 2014 Office and Lab Equipment $ 32,127 $ 32,127 Furniture and fixtures 11,556 11,556 43,683 43,683 Less accumulated depreciation (43,683 ) (43,229 ) Property & Equipment, Net $ - $ 454

NOTE 4. NOTES PAYABLE (Tables)

NOTE 4. NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2015
Note 4. Notes Payable Tables
Notes Payables	December 31, 2015 December 31, 2014 Note payable to related party, unsecured, due 8/3/2012, interest rate 0%. Currently in default. $ 1,950 $ 1,950 Notes payable to related party, unsecured, due 12/31/2012, interest rate 0%. Currently in default. $ 11,810 $ 11,810 Note payable to related party, unsecured, $731,763, 5-years at 0% simple interest, due 7/1/2016, payment amounts vary each month, various late penalties. $ 180,001 $ 726,763 Note payable to non-related party, unsecured, due 2/8/12, quarterly interest due, convertible at holder's option at $0.3235688 per TBT - DE share, interest rate 30%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 10,000 $ 10,000 Note payable to non-related party, unsecured, due 2/8/12, quarterly interest due, convertible at holder's option at $0.3235688 per TBT - DE share, interest rate 30%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 25,000 $ 25,000 Note payable to non-related party, unsecured, due 2/17/12, quarterly interest due, convertible at holder's option at $0.3235688 per TBT - DE share, interest rate 30%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 25,000 $ 25,000 Note payable to non-related party, unsecured, due 2/18/12, quarterly interest due, convertible at holder's option at $0.3235688 per TBT - DE share, interest rate 30%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 10,000 $ 10,000 Note payable to non-related party, unsecured, due 2/18/13, annual interest due, convertible at holder's option at $0.3235688 per TBT-DE share, interest rate 18%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 750 $ 750 Note payable to non-related party, unsecured, due 2/18/13, annual interest due, convertible at holder's option at $0.3235688 per TBT-DE share, interest rate 18%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 6,875 $ 6,875 Note payable to non-related party, unsecured, due 2/15/13, annual interest due, convertible at holder's option at $0.3235688 per TBT-DE share, interest rate 12%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 2,500 $ 2,500 Note payable to non-related party, unsecured, due 2/20/13, annual interest due, convertible at holder's option at $0.3235688 per TBT-DE share, interest rate 12%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 3,750 $ 3,750 Note payable to non-related party, unsecured, due 2/21/13, annual interest due, convertible at holder's option at $0.3235688 per TBT-DE. share, interest rate 12%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 2,625 $ 2,625 Note payable to non-related party, unsecured, due 3/20/13, annual interest due, convertible at holder's option at $0.3235688 per TBT-DE share, interest rate 12%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 5,433 $ 5,433 Note payable to non-related party, unsecured, due 3/22/13, annual interest due, convertible at holder's option at $0.3235688 per TBT-DE share, interest rate 12%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 3,203 $ 3,203 Note payable to non-related party, unsecured, due 4/19/13, annual interest due, convertible at holder's option at 51% of market as defined, interest rate 8%, conversion limited to total beneficial ownership of 4.99%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue and/or the continued conversion of the company's stock. $ - $ 6,605 Note payable to non-related party, unsecured, due 08/29/2013, simple interest 8% convertible at holder's option at $.249 per TBT-CA share. $ 15,000 $ 15,000 Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Note payable to related party, unsecured, due 03/01/2013, simple interest 9%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 5,000 $ 5,000 Note payable to non-related party, unsecured, due 12/13/2013, simple interest 7%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 5,342 Note payable to non-related party, unsecured, due 01/31/2013, simple interest 18%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 3,938 $ 3,938 Note payable to non-related party, unsecured, due 01/07/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 15,000 Note payable to non-related party, unsecured, due 01/15/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 5,000 Note payable to non-related party, unsecured, due 01/20/2014, simple interest 7%, default interest 10%, $ - $ 65,272 Stock option issued as an additional transaction cost for receipt of funds from note payable. Note payable to related party, unsecured, due 01/23/2014, simple interest 9%. Currently in default. $ 50,000 $ 50,000 Note payable to non-related party, unsecured, due 03/28/2013, $13,000 in interest (1 month). $ - $ 17,000 Note payable to non-related party, unsecured, due 04/28/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 9,440 Note payable to non-related party, unsecured, due 05/05/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 50,060 Note payable to related party, unsecured, due 07/02/2014, simple interest 9%. $ 15,000 $ 15,000 Note payable to non-related party, unsecured, due 09/19/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 10,000 Note payable to non-related party, unsecured, due 07/29/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 1,900 Note payable to non-related party, unsecured, due 07/25/2013, simple interest 18%. Currently in default. $ 2,000 $ 2,000 Note payable to non-related party, unsecured, due 09/19/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 65,000 Note payable to non-related party, unsecured, due 12/27/2013, simple interest 9% quarterly, Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 15,000 $ 15,000 Note payable to non-related party, unsecured, due 09/29/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 20,000 Note payable to non-related party, unsecured, due 10/28/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 2,500 Note payable to non-related party, unsecured, due 10/29/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 10,000 Note payable to non-related party, unsecured, due 11/10/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 5,000 Note payable to related party, unsecured, due 11/12/2014, simple interest 9%, Convertible at $0.04 per share, currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 11,000 $ 11,000 Note payable to non-related party, unsecured, due 11/20/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 20,000 Note payable to non-related party, unsecured, due 12/02/2014, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 5,000 Note payable to non-related party, unsecured, due 1/27/2014, simple interest 10%, $ - $ 4,235 Note payable to non-related party, unsecured, due 1/07/2015, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 25,000 Note payable to non-related party, unsecured, due 1/28/2015, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 1,253 Note payable to non-related party, unsecured, due 1/29/2015, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 3,500 Note payable to non-related party, unsecured, due 2/10/2015, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 990 Note payable to non-related party, unsecured, due 2/17/2015, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 4,500 Note payable to non-related party, unsecured, due 2/20/2015, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 5,000 Note payable to non-related party, unsecured, due 3/10/2015, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 2,500 Note payable to non-related party, unsecured, due 3/31/2015, simple interest 7%, default interest 10%, Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 2,500 Note payable to non-related party, unsecured, due 4/03/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 5,890 Note payable to related party, unsecured, due 4/08/2015, simple interest 7%, Convertible at $0.0072 per share. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. $ 15,000 $ 15,000 Note payable to non-related party, unsecured, due 4/10/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 4,331 Note payable to non-related party, unsecured, due 4/27/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 2,500 Note payable to non-related party, unsecured, due 5/13/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 5,360 Note payable to non-related party, unsecured, due 5/26/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 895 Note payable to non-related party, unsecured, due 9/11/2014, simple interest 10%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ 5,000 $ 5,000 Note payable to non-related party, unsecured, due 6/10/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 3,207 Note payable to non-related party, unsecured, due 6/17/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 600 Note payable to related party, unsecured, due 8/05/2015, simple interest 7%, default interest 10%. Currently in default. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ 10,000 $ 10,000 Note payable to non-related party, unsecured, due 7/09/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 3,750 Note payable to non-related party, unsecured, due 9/03/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 1,000 Note payable to non-related party, unsecured, due 10/19/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 1,486 Note payable to non-related party, unsecured, due 10/22/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 3,500 Note payable to non-related party, unsecured, due 10/28/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 4,360 Note payable to non-related party, unsecured, due 11/11/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 5,810 Note payable to non-related party, unsecured, due 11/19/2015, simple interest 7%, default interest 10%. Stock option issued as an additional transaction cost for receipt of funds from note payable. $ - $ 15,000 Note payable to related party unsecured, due 12/02/2015, simple interest 7%, default interest 10%. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Currently in default. $ 106,334 $ 214,334 Note payable to non-related party, unsecured, due 3/26/2016, simple interest 8%, convertible at $0.0017 per share. Principal balance including interest to be paid upon the receipt of equity funding and/or sales revenue. Currently in default. $ 25,000 $ - Note payable to related party, unsecured, due 4/11/2016, simple interest 10%. $ 13,000 $ - Note payable to related party, unsecured, due 11/11/2015, simple interest 10%. Currently in default. $ 45,000 $ - Note payable to non-related party, unsecured, due 11/11/2015, simple interest 10%. Currently in default. $ 2,500 $ - Note payable to related party, unsecured, due 12/26/2015, simple interest 10%. Currently in default. $ 25,000 $ - $ 652,669 $ 1,617,217 Less note discounts (6,250 ) (5,000 ) Less current - related parties (489,095 ) (697,225 ) Less current – non-related parties (157,324 ) (871,694 ) Long-term – related parties $ - $ 43.298
Principal payments	Required principal payments from December 31, 2015 forward are as follows: 2016 $ 652,669 2017 $ - 2018 $ - 2019 $ - 2020 $ - $ 652,669

NOTE 5. INCOME TAXES (Tables)

NOTE 5. INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2015
Note 5. Income Taxes Tables
Summary of deferred tax assets	The effects of temporary differences that gives rise to significant portions of deferred tax assets at December 31, 2015 and 2014 are as follows: Dec. 31, 2015 Dec. 31, 2014 Deferred tax asset Federal $ 1,057,000 $ 958,000 State 353,000 319,000 Valuation allowance (1,410,000 ) (1,277,000 ) Net deferred tax asset $ - $ -

NOTE 6. STOCK OPTIONS AND SUB21

NOTE 6. STOCK OPTIONS AND SUBSCRIPTIONS PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2015
Note 6. Stock Options And Subscriptions Payable Tables
Summary of stock option activity for California	A summary of stock option activity for California is as follows: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2014 2,500 $ .10 Granted - - Exercised - - Forfeited 2,500 .10 Outstanding at December 31, 2015 - $ -
Summary of stock option activity for Delaware	A summary of stock option activity for Delaware is as follows: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2014 13,755,046 $ .0295 Granted 16,282,995 .0015 Exercised - - Forfeited - - Outstanding at December 31, 2015 30,038,041 $ .0143
Schedule of common stock options and warrants Delaware outstanding	Following is a summary of the status of options for Delaware outstanding at December 31, 2015: Exercise Price Number of Shares Remaining Contractual Life Weighted Average Exercise Price Exercised at December 31, $ 0.0900 29,678 2 years 0.0900 - $ 0.1700 83,333 3 years 0.1700 - $ 0.1700 27,778 3 years 0.1700 - $ 0.1700 362,624 3 years 0.1700 - $ 0.1300 80,914 3 years 0.1300 - $ 0.1300 429,086 3 years 0.1300 - $ 0.0600 38,000 3 years 0.0600 - $ 0.0400 250,000 3 years 0.0400 - $ 0.0400 1,625,000 3 years 0.0400 - $ 0.0500 400,000 3 years 0.0500 - $ 0.0400 75,000 3 years 0.0400 - $ 0.0400 300,000 3 years 0.0400 - $ 0.0200 300,000 3 years 0.0200 - $ 0.0200 1,200,000 3 years 0.0200 - $ 0.0400 150,000 3 years 0.0400 - $ 0.0125 1,200,000 4 years 0.0125 $ 0.0150 50,137 4 years 0.0150 - $ 0.0150 140,000 4 years 0.0150 - $ 0.0190 31,256 4 years 0.0190 - $ 0.0161 167,702 4 years 0.0161 - $ 0.0147 204,082 4 years 0.0147 - $ 0.0200 75,000 4 years 0.0200 - $ 0.0198 75,758 4 years 0.0198 - $ 0.0213 165,915 4 years 0.0213 - $ 0.0195 133,262 4 years 0.0195 - $ 0.0188 79,787 4 years 0.0188 - $ 0.0140 229,714 4 years 0.0140 - $ 0.0190 50,000 4 years 0.0190 - $ 0.0127 42,283 4 years 0.0127 - $ 0.0090 213,833 4 years 0.0090 - $ 0.0074 48,649 4 years 0.0074 - $ 0.0060 375,000 4 years 0.0060 - $ 0.0098 612,245 4 years 0.0098 - $ 0.0098 61,224 4 years 0.0098 - $ 0.2500 25,000 4 years 0.2500 - $ 0.0680 450,000 4 years 0.0680 - $ 0.0072 123,828 4 years 0.0072 - $ 0.0056 375,000 4 years 0.0056 - $ 0.0070 250,000 4 years 0.0070 - $ 0.0070 373,714 4 years 0.0070 - $ 0.0041 850,244 4 years 0.0041 - $ 0.0045 2,000,000 4 years 0.0045 - $ 0.0024 150,000 5 years 0.0024 - $ 0.0010 7,625,544 5 years 0.0010 - $ 0.0024 1,770,000 5 years 0.0024 - $ 0.0023 400,782 5 years 0.0023 - $ 0.0012 275,000 5 years 0.0012 - $ 0.0017 1,764,706 5 years 0.0017 - $ 0.0018 2,463,333 5 years 0.0018 - $ 0.0021 285,714 5 years 0.0021 - $ 0.0018 333,333 5 years 0.0018 - $ 0.0018 1,083,333 5 years 0.0018 - $ 0.0018 131,250 5 years 0.0018 - Total 30,038,041 0.0143

NOTE 9. COMMITMENTS AND CONTI22

NOTE 9. COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2015
Note 9. Commitments And Contingencies Tables
Schedule of future minimum annual payments	As of December 31, 2015, future minimum annual payments under operating lease agreements for years ending December 31 are as follows. 2016 2017 2018 2019 2020 Total Operating leases 49,200 49,200 49,200 24,600 - 172,200 $ 49,200 $ 49,200 $ 49,200 $ 24,600 $ - $ 172,200

NOTE 1. ORGANIZATION, OPERATI23

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	Dec. 31, 2015	Dec. 31, 2014
Note 1. Organization Operations And Summary Of Significant Accounting Policies Details Narrative
Ownership interests	1.38%	1.38%

NOTE 2. RELATED PARTY TRANSAC24

NOTE 2. RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Note 2. Related Party Transactions Details Narrative
Payables due to officers, shareholders and former management	$ 412,656	$ 296,265

NOTE 3. PROPERTY & EQUIPMENT (D

NOTE 3. PROPERTY & EQUIPMENT (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Note 3. Property Equipment Details
Office and Lab Equipment	$ 32,127	$ 32,127
Furniture and fixtures	11,556	11,556
Gross Fixed Assets	43,683	43,683
Less accumulated depreciation	$ (43,683)	(43,229)
Property & Equipment, Net		$ 454

NOTE 3. PROPERTY & EQUIPMENT 26

NOTE 3. PROPERTY & EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Note 3. Property Equipment Details Narrative
Depreciation expense	$ 454	$ 776

NOTE 4. NOTES PAYABLE (Details)

NOTE 4. NOTES PAYABLE (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Notes Payable	$ 652,669	$ 1,617,217
Less note discounts	(6,250)	(5,000)
Less current - related parties	(489,095)	(697,225)
Less current non-related parties	$ (157,324)	(871,694)
Long-term related parties		43,298
Note payable 1 [Member]
Notes Payable	$ 1,950	1,950
Note payable 2 [Member]
Notes Payable	11,810	11,810
Note payable 3 [Member]
Notes Payable	180,001	726,763
Note payable 4 [Member]
Notes Payable	10,000	10,000
Note payable 5 [Member]
Notes Payable	25,000	25,000
Note payable 6 [Member]
Notes Payable	25,000	25,000
Note payable 7 [Member]
Notes Payable	10,000	10,000
Note payable 8 [Member]
Notes Payable	750	750
Note payable 9 [Member]
Notes Payable	6,875	6,875
Note payable 10 [Member]
Notes Payable	2,500	2,500
Note payable 11 [Member]
Notes Payable	3,750	3,750
Note payable 12 [Member]
Notes Payable	2,625	2,625
Note payable 13 [Member]
Notes Payable	5,433	5,433
Note payable 14 [Member]
Notes Payable	$ 3,203	3,203
Note payable 15 [Member]
Notes Payable		6,605
Note payable 16 [Member]
Notes Payable	$ 15,000	15,000
Note payable 17 [Member]
Notes Payable	$ 5,000	5,000
Note payable 18 [Member]
Notes Payable		5,342
Note payable 19 [Member]
Notes Payable	$ 3,938	3,938
Note payable 20 [Member]
Notes Payable		15,000
Note payable 21 [Member]
Notes Payable		5,000
Note payable 22 [Member]
Notes Payable		65,272
Note payable 23 [Member]
Notes Payable	$ 50,000	50,000
Note payable 24 [Member]
Notes Payable		17,000
Note payable 25 [Member]
Notes Payable		9,440
Note payable 26 [Member]
Notes Payable		50,060
Note payable 27 [Member]
Notes Payable	$ 15,000	15,000
Note payable 28 [Member]
Notes Payable		10,000
Note payable 29 [Member]
Notes Payable		1,900
Note payable 30 [Member]
Notes Payable	$ 2,000	2,000
Note payable 31 [Member]
Notes Payable		65,000
Note payable 32 [Member]
Notes Payable	$ 15,000	15,000
Note payable 33 [Member]
Notes Payable		20,000
Note payable 34 [Member]
Notes Payable		2,500
Note payable 35 [Member]
Notes Payable		10,000
Note payable 36 [Member]
Notes Payable		5,000
Note payable 37 [Member]
Notes Payable	$ 11,000	11,000
Note payable 38 [Member]
Notes Payable		20,000
Note payable 39 [Member]
Notes Payable		5,000
Note payable 40 [Member]
Notes Payable		4,235
Note payable 41 [Member]
Notes Payable		25,000
Note payable 42 [Member]
Notes Payable		1,253
Note payable 43 [Member]
Notes Payable		3,500
Note payable 44 [Member]
Notes Payable		990
Note payable 45 [Member]
Notes Payable		4,500
Note payable 46 [Member]
Notes Payable		5,000
Note payable 47 [Member]
Notes Payable		2,500
Note payable 48 [Member]
Notes Payable		2,500
Note payable 49 [Member]
Notes Payable		5,890
Note payable 50 [Member]
Notes Payable	$ 15,000	15,000
Note payable 51 [Member]
Notes Payable		4,331
Note payable 52 [Member]
Notes Payable		2,500
Note payable 53 [Member]
Notes Payable		5,360
Note payable 54 [Member]
Notes Payable		895
Note payable 55 [Member]
Notes Payable	$ 5,000	5,000
Note payable 56 [Member]
Notes Payable		3,207
Note payable 57 [Member]
Notes Payable		600
Note payable 58 [Member]
Notes Payable	$ 10,000	10,000
Note payable 59 [Member]
Notes Payable		3,750
Note payable 60 [Member]
Notes Payable		1,000
Note payable 61 [Member]
Notes Payable		1,486
Note payable 62 [Member]
Notes Payable		3,500
Note payable 63 [Member]
Notes Payable		4,360
Note payable 64 [Member]
Notes Payable		5,810
Note payable 65 [Member]
Notes Payable		15,000
Note payable 66 [Member]
Notes Payable	$ 106,334	$ 214,334
Note payable 67 [Member]
Notes Payable	25,000
Note payable 68 [Member]
Notes Payable	13,000
Note payable 69 [Member]
Notes Payable	45,000
Note payable 70 [Member]
Notes Payable	2,500
Note payable 71 [Member]
Notes Payable	$ 25,000

NOTE 4. NOTES PAYABLE (Details

NOTE 4. NOTES PAYABLE (Details 1)	Dec. 31, 2015USD ($)
Note 4. Notes Payable Details 1
2,016	$ 652,669
2,017
2,018
2,019
2,020
Total principal payment	$ 652,669

NOTE 4. NOTES PAYABLE (Detail29

NOTE 4. NOTES PAYABLE (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Interest expense	$ 198,327	$ 188,046
Beneficial Conversion Feature Interest Expense	23,750	32,996
Note discount	6,250	5,000
Borrowing under convertible notes		110,000
Convertible Notes	103,395	103,395
Fair value adjustments - equity obligation	$ (25,456)	21,559
Dividend yield	0.00%
Expected life	1 year
Fair value derivative liability	$ 0	$ 25,456
Minimum [Member]
Risk free interest rate	0.10%
Volatility	128.00%
Maximum [Member]
Risk free interest rate	0.21%
Volatility	354.00%

NOTE 5. INCOME TAXES (Details)

NOTE 5. INCOME TAXES (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Deferred tax asset
Federal	$ 1,057,000	$ 958,000
State	353,000	319,000
Valuation allowance	$ (1,410,000)	$ (1,277,000)
Net deferred tax asset

NOTE 5. INCOME TAXES (Details N

NOTE 5. INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Note 5. Income Taxes Details Narrative
Net operating loss carry forwards	$ 7,048,000	$ 6,383,000
Carryforward expiration year	2,035	2,035
Deferred tax asset	$ 1,410,000	$ 1,277,000
Rate of net operating losses offset by valuation allowance	100.00%	100.00%
Change in the valuation allowance	$ 133,000	$ 123,000

NOTE 6. STOCK OPTIONS AND SUB32

NOTE 6. STOCK OPTIONS AND SUBSCRIPTIONS PAYABLE (Details)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Weighted Average Exercise Price
Outstanding at end of period	$ 0.0143
California
Number of Shares
Outstanding at beginning of period | shares	2,500
Granted | shares
Exercised | shares
Forfeited | shares	2,500
Outstanding at end of period | shares
Weighted Average Exercise Price
Outstanding at beginning of period	$ 0.1
Granted
Exercised
Forfeited	$ 0.1
Outstanding at end of period
Delaware
Number of Shares
Outstanding at beginning of period | shares	13,755,046
Granted | shares	16,282,995
Exercised | shares
Forfeited | shares
Outstanding at end of period | shares	30,038,041
Weighted Average Exercise Price
Outstanding at beginning of period	$ 0.0295
Granted	$ 0.0015
Exercised
Forfeited
Outstanding at end of period	$ 0.0143

NOTE 6. STOCK OPTIONS AND SUB33

NOTE 6. STOCK OPTIONS AND SUBSCRIPTIONS PAYABLE (Details 1)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Number of Shares | shares	30,038,041
Weighted Average Exercise Price	$ 0.0143
0.0900 Delaware
Exercise Price	$ 0.0900
Number of Shares | shares	29,678
Weighted Average Remaining Contractual Life (Years)	2 years
Weighted Average Exercise Price	$ 0.0900
Exercised at December 31, 2014 | shares
0.1700 Delaware
Exercise Price	$ 0.1700
Number of Shares | shares	83,333
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.1700
Exercised at December 31, 2014 | shares
0.1700 Delaware
Exercise Price	$ 0.1700
Number of Shares | shares	27,778
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.1700
Exercised at December 31, 2014 | shares
0.1700 Delaware
Exercise Price	$ 0.1700
Number of Shares | shares	362,624
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.1700
Exercised at December 31, 2014 | shares
0.1300 Delaware
Exercise Price	$ 0.1300
Number of Shares | shares	80,914
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.1300
Exercised at December 31, 2014 | shares
0.1300 Delaware
Exercise Price	$ 0.1300
Number of Shares | shares	429,086
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.1300
Exercised at December 31, 2014 | shares
0.0600 Delaware
Exercise Price	$ 0.0600
Number of Shares | shares	38,000
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.0600
Exercised at December 31, 2014 | shares
0.0400 Delaware
Exercise Price	$ 0.0400
Number of Shares | shares	250,000
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.0400
Exercised at December 31, 2014 | shares
0.0400 Delaware
Exercise Price	$ 0.0400
Number of Shares | shares	1,625,000
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.0400
Exercised at December 31, 2014 | shares
0.0500 Delaware
Exercise Price	$ 0.0500
Number of Shares | shares	400,000
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.0500
Exercised at December 31, 2014 | shares
0.0400 Delaware
Exercise Price	$ 0.0400
Number of Shares | shares	75,000
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.0400
Exercised at December 31, 2014 | shares
0.0400 Delaware
Exercise Price	$ 0.0400
Number of Shares | shares	300,000
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.0400
Exercised at December 31, 2014 | shares
0.0200 Delaware
Exercise Price	$ 0.0200
Number of Shares | shares	300,000
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.0200
Exercised at December 31, 2014 | shares
0.0200 Delaware
Exercise Price	$ 0.0200
Number of Shares | shares	1,200,000
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.0200
Exercised at December 31, 2014 | shares
0.0400 Delaware
Exercise Price	$ 0.0400
Number of Shares | shares	150,000
Weighted Average Remaining Contractual Life (Years)	3 years
Weighted Average Exercise Price	$ 0.0400
Exercised at December 31, 2014 | shares
0.0125 Delaware
Exercise Price	$ 0.0125
Number of Shares | shares	1,200,000
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0125
0.0150 Delaware
Exercise Price	$ 0.0150
Number of Shares | shares	50,137
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0150
Exercised at December 31, 2014 | shares
0.0150 Delaware
Exercise Price	$ 0.0150
Number of Shares | shares	140,000
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0150
Exercised at December 31, 2014 | shares
0.0190 Delaware
Exercise Price	$ 0.0190
Number of Shares | shares	31,256
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0190
Exercised at December 31, 2014 | shares
0.0161 Delaware
Exercise Price	$ 0.0161
Number of Shares | shares	167,702
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0161
Exercised at December 31, 2014 | shares
0.0147 Delaware
Exercise Price	$ 0.0147
Number of Shares | shares	204,082
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0147
Exercised at December 31, 2014 | shares
0.0200 Delaware
Exercise Price	$ 0.0200
Number of Shares | shares	75,000
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0200
Exercised at December 31, 2014 | shares
0.0198 Delaware
Exercise Price	$ 0.0198
Number of Shares | shares	75,758
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0198
Exercised at December 31, 2014 | shares
0.0213 Delaware
Exercise Price	$ 0.0213
Number of Shares | shares	165,915
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0213
Exercised at December 31, 2014 | shares
0.0195 Delaware
Exercise Price	$ 0.0195
Number of Shares | shares	133,262
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0195
Exercised at December 31, 2014 | shares
0.0188 Delaware
Exercise Price	$ 0.0188
Number of Shares | shares	79,787
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0188
Exercised at December 31, 2014 | shares
0.0140 Delaware
Exercise Price	$ 0.0140
Number of Shares | shares	229,714
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0140
Exercised at December 31, 2014 | shares
0.0190 Delaware
Exercise Price	$ 0.0190
Number of Shares | shares	50,000
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0190
Exercised at December 31, 2014 | shares
0.0127 Delaware
Exercise Price	$ 0.0127
Number of Shares | shares	42,283
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0127
Exercised at December 31, 2014 | shares
0.0090 Delaware
Exercise Price	$ 0.0090
Number of Shares | shares	213,833
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0090
Exercised at December 31, 2014 | shares
0.0074 Delaware
Exercise Price	$ 0.0074
Number of Shares | shares	48,649
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0074
Exercised at December 31, 2014 | shares
0.0060 Delaware
Exercise Price	$ 0.0060
Number of Shares | shares	375,000
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0060
Exercised at December 31, 2014 | shares
0.0098 Delaware
Exercise Price	$ 0.0098
Number of Shares | shares	612,245
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0098
Exercised at December 31, 2014 | shares
0.0098 Delaware
Exercise Price	$ 0.0098
Number of Shares | shares	61,224
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0098
Exercised at December 31, 2014 | shares
0.2500 Delaware
Exercise Price	$ 0.2500
Number of Shares | shares	25,000
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.2500
Exercised at December 31, 2014 | shares
0.0680 Delaware
Exercise Price	$ 0.0680
Number of Shares | shares	450,000
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0680
Exercised at December 31, 2014 | shares
0.0072 Delaware
Exercise Price	$ 0.0072
Number of Shares | shares	123,828
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0072
Exercised at December 31, 2014 | shares
0.0056 Delaware
Exercise Price	$ 0.0056
Number of Shares | shares	375,000
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0056
Exercised at December 31, 2014 | shares
0.0070 Delaware
Exercise Price	$ 0.0070
Number of Shares | shares	250,000
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0070
Exercised at December 31, 2014 | shares
0.0070 Delaware
Exercise Price	$ 0.0070
Number of Shares | shares	373,714
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0070
Exercised at December 31, 2014 | shares
0.0041 Delaware
Exercise Price	$ 0.0041
Number of Shares | shares	850,244
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0041
Exercised at December 31, 2014 | shares
0.0045 Delaware
Exercise Price	$ 0.0045
Number of Shares | shares	2,000,000
Weighted Average Remaining Contractual Life (Years)	4 years
Weighted Average Exercise Price	$ 0.0045
Exercised at December 31, 2014 | shares
0.0024 Delaware
Exercise Price	$ 0.0024
Number of Shares | shares	150,000
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.0024
Exercised at December 31, 2014 | shares
0.0010 Delaware
Exercise Price	$ 0.0010
Number of Shares | shares	7,625,544
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.0010
Exercised at December 31, 2014 | shares
0.0024 Delaware
Exercise Price	$ 0.0024
Number of Shares | shares	1,770,000
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.0024
Exercised at December 31, 2014 | shares
0.0023 Delaware
Exercise Price	$ 0.0023
Number of Shares | shares	400,782
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.0023
Exercised at December 31, 2014 | shares
0.0012 Delaware
Exercise Price	$ 0.0012
Number of Shares | shares	275,000
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.0012
Exercised at December 31, 2014 | shares
0.0017 Delaware
Exercise Price	$ 0.0017
Number of Shares | shares	1,764,706
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.0017
Exercised at December 31, 2014 | shares
0.0018 Delaware
Exercise Price	$ 0.0018
Number of Shares | shares	2,463,333
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.0018
Exercised at December 31, 2014 | shares
0.0021 Delaware
Exercise Price	$ 0.0021
Number of Shares | shares	285,714
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.0021
Exercised at December 31, 2014 | shares
0.0018 Delaware
Exercise Price	$ 0.0018
Number of Shares | shares	333,333
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.0018
Exercised at December 31, 2014 | shares
0.0018 Delaware
Exercise Price	$ 0.0018
Number of Shares | shares	1,083,333
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.0018
Exercised at December 31, 2014 | shares
0.0018 Delaware
Exercise Price	$ 0.0018
Number of Shares | shares	131,250
Weighted Average Remaining Contractual Life (Years)	5 years
Weighted Average Exercise Price	$ 0.0018
Exercised at December 31, 2014 | shares

NOTE 6. STOCK OPTIONS AND SUB34

NOTE 6. STOCK OPTIONS AND SUBSCRIPTIONS PAYABLE (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Stock subscription payable - current	$ 55,882	$ 28,067
Non employee stock options [Member]
Stock option exercised		20,000
Outstanding balance		$ 2,500
Option terms expiration	January 2,015	January 2,015
Options exercisable exercise price		$ 0.10
Option expired	30,038,041	13,755,046
Option granted	16,282,995	8,403,633
Dividend yield	0.00%	0.00%
Expected lives	5 years	5 years
Compensation expense	$ 27,731	$ 69,886
Non employee stock options [Member] | Minimum [Member]
Risk free interest rate	1.37%	1.55%
Volatility rate	172.00%	147.00%
Non employee stock options [Member] | Maximum [Member]
Risk free interest rate	1.68%	1.77%
Volatility rate	174.00%	178.00%
Common Stock [Member]
Stock subscription payable - current	$ 55,868
Common stock issued for stock subscription payment	6,049,578
Preferred Stock [Member]
Stock subscription payable - current	$ 14
Common stock issued for stock subscription payment	1,388,575

NOTE 7. GOING CONCERN (Details

NOTE 7. GOING CONCERN (Details Narrative) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Note 7. Going Concern Details Narrative
Accumulated deficit	$ (16,468,956)	$ (15,777,222)

NOTE 9. COMMITMENTS AND CONTI36

NOTE 9. COMMITMENTS AND CONTINGENCIES (Details)	Dec. 31, 2015USD ($)
2,016	$ 49,200
2,017	49,200
2,018	49,200
2,019	$ 24,600
2,020
Total	$ 172,200
Operating Leases [Member]
2,016	49,200
2,017	49,200
2,018	49,200
2,019	$ 24,600
2,020
Total	$ 172,200

NOTE 9. COMMITMENTS AND CONTI37

NOTE 9. COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Note 9. Commitments And Contingencies Details Narrative
Rent expense	$ 24,600	$ 0